Abstract Details

Title Role of Glial Fibrillary Acidic Protein as a Biomarker in Differentiating Intracerebral Hemorrhage From Ischemic Stroke And Stroke Mimics: A Meta-Analysis

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 4-013

Objective To determine the potential role of GFAP as a biomarker for differentiating ICH (Intracerebral hemorrhage) from ischemic stroke (IS) and stroke mimics using a meta-analysis approach

Background

Stroke is the second leading cause of death and third cause of disability worldwide. Studies have suggested that Glial fibrillary acidic protein (GFAP) can be used as a blood based biomarker to distinguish ischemic stroke (IS) and intracerebral hemorrhage (ICH).

Design/Methods MeSH Search terms were used for literature search: ("STROKE" [Mesh] OR "BIOMARKER" [Title/Abstract] OR "GFAP" [Title/Abstract])] OR "SPECIFICITY" OR "SENSTIVITY" at various search engines like PubMed, Google scholar, Trip database, clinicaltrial.gov for articles from inception through April 2019 using filter ‘human subjects’.

Results

A Pooled analysis of 12 studies suggested that GFAP if used as a biomarker to differentiate between different types of strokes (ICH from IS and mimics) had a sensitivity of 78% (95% CI: 67 to 86) and a specificity of 95%, (95% CI: 0.88 to 0.98). Positive likelihood ratio (LR) was 14.3 and negative LR was 0.23.

Conclusions

Our meta-analysis suggests that GFAP has a promising diagnostic accuracy for the differentiation of ICH from IS and mimics. Further, phase II and phase III diagnostic test studies are required to validate the findings before using GFAP as a blood based biomarker for clinical use.

Authors/Disclosures
PRESENTER	No disclosure on file
Shubham Misra, PhD (Yale University)	Dr. Misra has nothing to disclose.
Kameshwar Prasad, MD (Rajendra Institute of Medical Sciences, Ranchi)	The institution of Prof. Prasad has received research support from Government of India Departments of Health Research and Biotechnology.